ClinicalTrials.gg
RecruitingNCT07124117Updated Jan 5, 2026

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of OBI-902 in Advanced Solid Tumor, sponsored by OBI Pharma, Inc. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by OBI Pharma, Inc · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
147
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a 3-part study. Phase 1a (dose escalation) is designed to assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and putative recommended phase 2 dose (RP2D) of study drug as monotherapy. Phase 1b (Cohort Expansion) is intended to further characterize the safety and preliminary antitumor activity of the putative RP2D of OBI-902 in selected tumor types. Phase 2 (Randomized Dose Optimization Cohorts) is intended to determine the optimal RP2D of OBI-902 in selected tumor types, before advancing to larger Phase 3 trials.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

OBI Pharma, Inc is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants, 18 years of age or older at the time of consent
  2. Provide written prior to performing any study-related procedure
  3. or cytologically confirmed participants with or advanced solid tumor that is not curable with local therapies
  4. Participants must have been treated with established standard-of-care therapy, andphysicians have determined that such established therapy is not sufficiently efficacious, or patients have declined to receive standard-of-care therapy. In the latter case, the source documentation must state the effective therapies the participant is declining.
  5. (i.e., at least one measurable lesion per 1.1)
  6. (ECOG) performance status of 0 or 1
  7. Adequate organ function defined as:

    a. Hepatic:

    i. Serum ≤3 × (ULN), ≤5 × ULN in the presence of liver metastases

    i. Serum AST ≤3 × ULN, ≤5 × ULN in presence of liver metastases

    ii. Serum ≤1.5 × ULN (unless due to Gilbert's syndrome (typically elevated total bilirubin of 1-5 mg/dL with a normal direct bilirubin) or hemolysis)

    b. >60 mL/minute using Modification of Diet in Renal Disease equation

    c. Hematologic:

    i. ≥1,500/µL (>1,200/µL in Duffy antigen-null participants)

    ii. ≥100,000/µL

    iii. ≥8 g/dL

  8. Participants must be willing and able to comply with all protocol-required assessments, visits, and procedures, including evaluable pretreatment tumor . Archival tumor biopsies are acceptable at baseline.
  9. Females of must have negative serum pregnancy test prior to starting study therapy and agree to use a reliable form of during the study treatment period and for at least 7 months following the last dose of study drug.
  10. Participants not of childbearing potential (i.e., permanently sterilized, ) can be included in the trial. Postmenopausal is defined as 12 months with no menses without an alternative medical cause. Male participants must agree to use an adequate method of contraception during the study treatment period and for at least 4 months following the last dose of study drug.
  11. Participants with (HIV) infection or with documented history of HIV infection are eligible if are ≥350 cells/μL and have an HIV viral load less than 200 copies/mL prior to enrollment. Participants on ART should be on an established dose for at least 4 weeks under stable condition.
  12. Participants with serological evidence of chronic infection or with documented history of HBV infection are eligible if they have an HBV viral load below the limit of quantification with or without concurrent viral suppressive therapy.
  13. Participants with a history of infection can be under curative antiviral treatment and have a viral load below the limit of quantification.
  14. Participants in Phase 1b (Cohort Expansion) - must have one of the following tumor types to be enrolled in the respective cohort:

    • Cohort 1: BTC (intra- and extrahepatic CCA, carcinoma of ampulla of Vater, and gallbladder disease)
    • Cohort 2: Gastric and GEJ cancer
    • Cohort 3: PROC

Exclusion criteria

Exclusion Criteria:

  1. Less than 3 weeks from prior cytotoxic chemotherapy or radiation therapy; and less than 5 half-lives or 3 weeks, whichever is shorter, from prior biologic therapies, prior to the first dose of OBI-902.
  2. Participants that have undergone a major surgical procedure (as defined by the investigator) or significant traumatic injury within 28 days prior to the first dose of OBI-902.
  3. Sensory or motor neuropathy of Grade 2 or greater.
  4. Participants with a history of solid organ transplants. Corneal transplant without therapy is allowed.
  5. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Grade 0 or 1 (using version 5.0), except for alopecia and laboratory values listed in the inclusion criteria.
  6. Receipt of any prior therapy targeting TROP2. (Phase 2 only)
  7. interval (QTcF) prolongation to >470 msec based on the average of the screening 12-lead ECGs
  8. Known to OBI-902 or its .
  9. Participants with known untreated central nervous system (CNS) . Participants with treated are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT]) during the screening period.
  10. Participants with significant clinical cardiac abnormality (e.g., clinical heart failure or unstable angina).
  11. Any medical comorbidity that is life-threatening or, in the opinion of the Investigator, renders the participant unsuitable for participation in a clinical trial due to possible noncompliance, would place the participant at an unacceptable risk and/or potential to affect interpretation of results of the study.
  12. Participants who are pregnant or breastfeeding.
  13. Is receiving any concurrent prohibited medications as listed in OBI-902-001 clinical protocol.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
147 participants (estimated)

Study arms

  • Experimental
    Phase 1a Dose Escalation: Cohort 1

    OBI-902 at dose level 1.6 mg/kg, Q3W

    Drug: OBI-902

  • Experimental
    Phase 1a Dose Escalation: Cohort 2

    OBI-902 at dose level 3.0 mg/kg, Q3W

    Drug: OBI-902

  • Experimental
    Phase 1a Dose Escalation: Cohort 3

    OBI-902 at dose level 4.5 mg/kg, Q3W

    Drug: OBI-902

  • Experimental
    Phase 1a Dose Escalation: Cohort 4

    OBI-902 at dose level 6.0 mg/kg, Q3W

    Drug: OBI-902

  • Experimental
    Phase 1a Dose Escalation: Cohort 5

    OBI-902 at dose level 8.0 mg/kg, Q3W

    Drug: OBI-902

  • Experimental
    Phase 1a Dose Escalation: Cohort 6

    OBI-902 at dose level 10.0 mg/kg, Q3W

    Drug: OBI-902

  • Experimental
    Phase 1b Cohort Expansion: Cohort 1

    OBI-902 at the putative RP2D determined during the Phase 1a Dose Escalation; biliary tract cancer cohort.

    Drug: OBI-902

  • Experimental
    Phase 1b Cohort Expansion: Cohort 2

    OBI-902 at the putative RP2D determined during the Phase 1a Dose Escalation; gastric and gastroesophageal cancer cohort.

    Drug: OBI-902

  • Experimental
    Phase 1b Cohort Expansion: Cohort 3

    OBI-902 at the putative RP2D determined during the Phase 1a Dose Escalation; platinum resistant ovarian cancer cohort.

    Drug: OBI-902

  • Experimental
    Phase 2 Randomized Dose Optimization Cohort: Cohort 1

    Randomized dose optimization cohort. Tumor type and/or population will be based on safety/tolerability, PK, and preliminary efficacy of OBI-902 from Phase 1 part of the study.

    Drug: OBI-902

  • Experimental
    Phase 2 Randomized Dose Optimization Cohort: Cohort 2

    Randomized dose optimization cohort. Tumor type and/or population will be based on safety/tolerability, PK, and preliminary efficacy of OBI-902 from Phase 1 part of the study.

    Drug: OBI-902

Interventions

  • DrugOBI-902

    OBI-902 is an antibody-drug conjugate study drug

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of OBI-902: incidence of adverse events (AEs) and serious adverse events (SAEs), changes in selected clinical laboratory parameters, cardiac parameters, and vital signs.

    To assess the safety and tolerability of OBI-902 when administered intravenously to participants with advanced solid tumors

    Time frame: Duration of study, up to 54 weeks

  2. Maximum tolerated dose (MTD) of OBI-902

    To determine the MTD of OBI-902 at which the pre-defined rate of dose limiting toxicities (DLTs) is not exceeded.

    Time frame: Duration of study, up to 54 weeks

  3. Preliminary antitumor activity of OBI-902 in selected tumor types - Objective Response Rate (ORR)

    Percentage of participants with ORR according to RECIST version 1.1 for each cohort

    Time frame: Duration of study, up to 54 weeks

  4. Preliminary antitumor activity of OBI-902 in selected tumor types - Duration of Response (DoR)

    Percentage of participants with DOR according to RECIST version 1.1 for each cohort

    Time frame: Duration of study, up to 54 weeks

  5. Preliminary antitumor activity of OBI-902 in selected tumor types - Clinical Benefit Rate (CBR)

    Percentage of participants with CBR according to RECIST version 1.1 for each cohort

    Time frame: Duration of study, up to 54 weeks

  6. Preliminary antitumor activity of OBI-902 in selected tumor types - Disease Control Rate (DCR)

    Percentage of participants with DCR according to RECIST version 1.1 for each cohort

    Time frame: Duration of study, up to 54 weeks

  7. Safety and tolerability of OBI-902 in Phase 1b/Phase 2: incidence of AEs, SAEs, and laboratory abnormalities.

    To further characterize safety and tolerability of OBI-902 as graded by NCI CTCAE version 5.0.

    Time frame: Duration of study, up to 54 weeks

  8. Optimal recommended phase 2 dose (RP2D) of OBI-902

    To determine the optimal RP2D of OBI-902 for larger Phase 3 trials

    Time frame: Duration of study, up to 54 weeks

Secondary outcomes

  1. Preliminary long-term efficacy of OBI-902 in selected tumor types

    PFS as assessed by the investigator and OS.

    Time frame: Duration of study, up to 54 weeks

  2. Pharmacokinetics (PK) of OBI-902 and exatecan: Peak Plasma Concentration (Cmax)

    To evaluate the serum Cmax of OBI-902 and exatecan

    Time frame: Duration of study, up to 54 weeks

  3. Pharmacokinetics (PK) of OBI-902 and exatecan: area under the concentration-time curve (AUC)

    To evaluate the serum AUC of OBI-902 and exatecan

    Time frame: Duration of study, up to 54 weeks

  4. Pharmacokinetics (PK) of OBI-902 and exatecan: half-life (T1/2)

    To evaluate the serum half-life of OBI-902 and exatecan

    Time frame: Duration of study, up to 54 weeks

  5. Pharmacokinetics (PK) of OBI-902 and exatecan: clearance (CL)

    To evaluate the serum clearance of OBI-902 and exatecan

    Time frame: Duration of study, up to 54 weeks

  6. Pharmacokinetics (PK) of OBI-902 and exatecan: volume distribution at steady state (Vdss)

    To evaluate the serum volume distribution at steady state of OBI-902 and exatecan

    Time frame: Duration of study, up to 54 weeks

  7. Immunogenicity of OBI-902

    To evaluate the immunogenicity of OBI-902 anti-drug antibodies (ADAs)

    Time frame: Duration of study, up to 54 weeks

07

Study locations

5 of 6 sites recruiting
  • Scripps Green Hospital
    La Jolla, California 92037, United States
    Recruiting
    • OBI Investigator Site · Principal investigator
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • OBI Investigator Site · Principal investigator
  • NEXT Oncology
    San Antonio, Texas 78229, United States
    Recruiting
    • OBI Investigator Site · Principal investigator
  • Wan Fan Hospital
    Taipei, Wenshan 116, Taiwan
    Recruiting
    • OBI Investigator Site · Principal investigator
  • Shuang Ho Hospital
    Taipei, Zhonghe 23561, Taiwan
    Active, not recruiting

    Not enrolling at this site.

  • China Medical University Hospital
    Taichung, 404327, Taiwan
    Recruiting
    • OBI Investigator Site · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Feb 2029, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 15, 2025
StartActual
Aug 4, 2025
Primary completionEst.
Feb 8, 2029
CompletionEst.
Feb 8, 2029
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07124117
Lead sponsor
OBI Pharma, Inc
Responsible party
Sponsor
First posted
Aug 15, 2025
Start date
Aug 4, 2025
Primary completion
Feb 8, 2029 (estimated)
Completion
Feb 8, 2029 (estimated)
Last update
Jan 5, 2026

Study contacts

OBI Pharma, Inc. Sponsor
Contact
clinicaltrials.gov-queries@obipharma.com
1-619-537-7821

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion